Peptide Coalition
Peptide Coalition: five members, plenty of dissent
I pictured a table crowded with these peptides. The sepsis trial supplied the first objection: a persuasive immune story, followed by a result that refused to cooperate.
Stations
TESTS, 2025
In a trial of 1,106 adults with sepsis across 22 centres, thymosin alpha-1 faced a brutally practical question: did fewer people die? The TESTS trial found no statistically significant reduction in 28-day mortality. Mortality was 23.4 per cent with the peptide and 24.1 per cent with placebo; the hazard ratio was 0.99, with a 95 per cent confidence interval of 0.77 to 1.27 and P equal to 0.93.
An earlier study had offered encouragement. In ETASS, involving 361 patients with severe sepsis, mortality was 26.0 per cent with treatment and 35.0 per cent in controls. Even there, the statistics were unsettled: nonstratified P equal to 0.062, log-rank P equal to 0.049. The larger, double-blind trial gave that hopeful story a much harder test.
TESTS gets my opening seat because a coalition worth listening to can accommodate an unwelcome answer. This finding concerns sepsis. It leaves the other proposed uses of thymosin alpha-1 to their own trials, while taking away an easy reason to call every immune effect a benefit.
Membership
Peptides are chains of amino acids, the building blocks of proteins. That common material admits a remarkably unruly group: a fragment inspired by gastric juice, a growth-hormone signal, a modified gut hormone, a thymic immune peptide and a melanocortin drug studied for sexual desire.
The temptation is to let the successes speak for the whole table. Semaglutide has a cardiovascular outcome trial in 17,604 adults. BPC-157 has a review counting three small human pilot studies. Their shared membership in the peptide category cannot transfer a result from one molecule to the other. The friction draws me in: why a mechanism can look compelling while a clinical result disappoints, and why a medicine can work while remaining quite limited in what it offers.
The comparison page puts peptide sequences, trial tags and outcomes alongside one another. The differences are the reason for the gathering.
Two kinds of disagreement
Thymosin alpha-1 presents a disagreement between earlier encouragement and a later null trial. PT-141 presents another: its pivotal trials detected improvements in desire and distress, yet the size and practical value of those changes remain open to argument. A negative result and a modest positive result deserve different conversations.
I distrust a collective claim about recovery, vitality or risk made on behalf of “peptides.” Each compound brings its own population, outcome and safety questions. There is enough interest here without making everyone vote together.
Start with thymosin alpha-1 and the sepsis results, or choose a compound below.
BPC-157
The sequence is precise. The human healing evidence is still small.
Sequence and tissue studies ›CJC-1295
An ingenious albumin attachment, a strong hormone signal and an unfinished clinical programme.
Chemistry and hormone findings ›Semaglutide
Weight, cardiovascular events and kidney events each get their own trial population.
Three clinical questions ›